Cluster of differentiation 19 chimeric antigen receptor T‑cell therapy in pediatric acute lymphoblastic leukemia (Review)
Chimeric antigen receptor (CAR) T cells have an unprecedented positive curative effect for hematological malignances. Most notably, cluster of differentiation 19 (CD19) CAR T-cell therapy for pediatric acute lymphoblastic leukemia is associated with a high complete remission rate and has aroused con...
Gespeichert in:
| Veröffentlicht in: | Oncology letters 2020-10, Vol.20 (4), p.1-36 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 36 |
|---|---|
| container_issue | 4 |
| container_start_page | 1 |
| container_title | Oncology letters |
| container_volume | 20 |
| creator | Fu, Zexin Zhou, Jinlei Chen, Rui Jin, Yihua Ni, Ting Qian, Lingbo Xiao, Chi |
| description | Chimeric antigen receptor (CAR) T cells have an unprecedented positive curative effect for hematological malignances. Most notably, cluster of differentiation 19 (CD19) CAR T-cell therapy for pediatric acute lymphoblastic leukemia is associated with a high complete remission rate and has aroused considerable attention in the medical field. However, it also causes a series of adverse reactions and increases the risk of recurrence. The present review examines the results of CD19 CAR T-cell therapy and lists its adverse effects. In addition, some of the mechanisms of recurrence are characterized and applicable strategies to address this challenging problem are proposed. |
| doi_str_mv | 10.3892/ol.2020.11897 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7412636</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A635402890</galeid><sourcerecordid>A635402890</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-1f4362ae006ccc96453102dbebdf5624d0aaab031bdd1d487dd66b2ef10c66413</originalsourceid><addsrcrecordid>eNptkstq3TAQhk1paUKaZfeCQkkXPtXNsr0phENvECiUdC1kaXysVLZcSU44dNNX6Cv2SSonIeSUSgsNo-__xYymKF4SvGFNS996t6GY4g0hTVs_KY5J3dKS4IY-fYhrflScxniF86oEaRrxvDhitMGUCHxc_Ny6JSYIyPfI2L6HAFOyKlk_IdIiPdgRgtVI5ewOJhRAw5x8QJd_fv3W4BxKAwQ175Gd0AwmS29xvSRAbj_Og--ciinnHCzfYbQKnX2Faws3b14Uz3rlIpzenyfFtw_vL7efyosvHz9vzy9KzVucStJzJqgCjIXWuhW8YgRT00Fn-kpQbrBSqsOMdMYQw5vaGCE6Cj3BWghO2Enx7s53XroRjM4VBuXkHOyowl56ZeXhzWQHufPXsuaECiaywdm9QfA_FohJjjauxasJ_BIl5YzXlajFir76B73yS5hyeStVs7qq-CNqpxxIO_U-v6tXU3kuWMUxbVqcqc1_qLxNbqP2E_Q25w8Erx8JBlAuDdG7Zf3NeAiWd6AOPsYA_UMzCJbrZEnv5DpZ8nay2F8Lg8AL</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2437375546</pqid></control><display><type>article</type><title>Cluster of differentiation 19 chimeric antigen receptor T‑cell therapy in pediatric acute lymphoblastic leukemia (Review)</title><source>Spandidos Publications Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Fu, Zexin ; Zhou, Jinlei ; Chen, Rui ; Jin, Yihua ; Ni, Ting ; Qian, Lingbo ; Xiao, Chi</creator><creatorcontrib>Fu, Zexin ; Zhou, Jinlei ; Chen, Rui ; Jin, Yihua ; Ni, Ting ; Qian, Lingbo ; Xiao, Chi</creatorcontrib><description>Chimeric antigen receptor (CAR) T cells have an unprecedented positive curative effect for hematological malignances. Most notably, cluster of differentiation 19 (CD19) CAR T-cell therapy for pediatric acute lymphoblastic leukemia is associated with a high complete remission rate and has aroused considerable attention in the medical field. However, it also causes a series of adverse reactions and increases the risk of recurrence. The present review examines the results of CD19 CAR T-cell therapy and lists its adverse effects. In addition, some of the mechanisms of recurrence are characterized and applicable strategies to address this challenging problem are proposed.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2020.11897</identifier><identifier>PMID: 32802160</identifier><language>eng</language><publisher>Athens: Spandidos Publications</publisher><subject>Acute lymphocytic leukemia ; Antigens ; B cells ; Cancer therapies ; Cell differentiation ; Chemotherapy ; Clinical medicine ; Clinical trials ; Combination drug therapy ; Cytokines ; Genetic engineering ; Health aspects ; Immunotherapy ; Leukemia ; Lymphocytes ; Oncology ; Patients ; Pediatrics ; Proteins ; Review ; Stem cells ; T cell receptors ; T cells ; Tisagenlecleucel ; Transplants & implants ; Tumor necrosis factor-TNF ; Young adults</subject><ispartof>Oncology letters, 2020-10, Vol.20 (4), p.1-36</ispartof><rights>COPYRIGHT 2020 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2020</rights><rights>Copyright: © Fu et al. 2020</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-1f4362ae006ccc96453102dbebdf5624d0aaab031bdd1d487dd66b2ef10c66413</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412636/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412636/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,27907,27908,53774,53776</link.rule.ids></links><search><creatorcontrib>Fu, Zexin</creatorcontrib><creatorcontrib>Zhou, Jinlei</creatorcontrib><creatorcontrib>Chen, Rui</creatorcontrib><creatorcontrib>Jin, Yihua</creatorcontrib><creatorcontrib>Ni, Ting</creatorcontrib><creatorcontrib>Qian, Lingbo</creatorcontrib><creatorcontrib>Xiao, Chi</creatorcontrib><title>Cluster of differentiation 19 chimeric antigen receptor T‑cell therapy in pediatric acute lymphoblastic leukemia (Review)</title><title>Oncology letters</title><description>Chimeric antigen receptor (CAR) T cells have an unprecedented positive curative effect for hematological malignances. Most notably, cluster of differentiation 19 (CD19) CAR T-cell therapy for pediatric acute lymphoblastic leukemia is associated with a high complete remission rate and has aroused considerable attention in the medical field. However, it also causes a series of adverse reactions and increases the risk of recurrence. The present review examines the results of CD19 CAR T-cell therapy and lists its adverse effects. In addition, some of the mechanisms of recurrence are characterized and applicable strategies to address this challenging problem are proposed.</description><subject>Acute lymphocytic leukemia</subject><subject>Antigens</subject><subject>B cells</subject><subject>Cancer therapies</subject><subject>Cell differentiation</subject><subject>Chemotherapy</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Combination drug therapy</subject><subject>Cytokines</subject><subject>Genetic engineering</subject><subject>Health aspects</subject><subject>Immunotherapy</subject><subject>Leukemia</subject><subject>Lymphocytes</subject><subject>Oncology</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Proteins</subject><subject>Review</subject><subject>Stem cells</subject><subject>T cell receptors</subject><subject>T cells</subject><subject>Tisagenlecleucel</subject><subject>Transplants & implants</subject><subject>Tumor necrosis factor-TNF</subject><subject>Young adults</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkstq3TAQhk1paUKaZfeCQkkXPtXNsr0phENvECiUdC1kaXysVLZcSU44dNNX6Cv2SSonIeSUSgsNo-__xYymKF4SvGFNS996t6GY4g0hTVs_KY5J3dKS4IY-fYhrflScxniF86oEaRrxvDhitMGUCHxc_Ny6JSYIyPfI2L6HAFOyKlk_IdIiPdgRgtVI5ewOJhRAw5x8QJd_fv3W4BxKAwQ175Gd0AwmS29xvSRAbj_Og--ciinnHCzfYbQKnX2Faws3b14Uz3rlIpzenyfFtw_vL7efyosvHz9vzy9KzVucStJzJqgCjIXWuhW8YgRT00Fn-kpQbrBSqsOMdMYQw5vaGCE6Cj3BWghO2Enx7s53XroRjM4VBuXkHOyowl56ZeXhzWQHufPXsuaECiaywdm9QfA_FohJjjauxasJ_BIl5YzXlajFir76B73yS5hyeStVs7qq-CNqpxxIO_U-v6tXU3kuWMUxbVqcqc1_qLxNbqP2E_Q25w8Erx8JBlAuDdG7Zf3NeAiWd6AOPsYA_UMzCJbrZEnv5DpZ8nay2F8Lg8AL</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Fu, Zexin</creator><creator>Zhou, Jinlei</creator><creator>Chen, Rui</creator><creator>Jin, Yihua</creator><creator>Ni, Ting</creator><creator>Qian, Lingbo</creator><creator>Xiao, Chi</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20201001</creationdate><title>Cluster of differentiation 19 chimeric antigen receptor T‑cell therapy in pediatric acute lymphoblastic leukemia (Review)</title><author>Fu, Zexin ; Zhou, Jinlei ; Chen, Rui ; Jin, Yihua ; Ni, Ting ; Qian, Lingbo ; Xiao, Chi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-1f4362ae006ccc96453102dbebdf5624d0aaab031bdd1d487dd66b2ef10c66413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acute lymphocytic leukemia</topic><topic>Antigens</topic><topic>B cells</topic><topic>Cancer therapies</topic><topic>Cell differentiation</topic><topic>Chemotherapy</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Combination drug therapy</topic><topic>Cytokines</topic><topic>Genetic engineering</topic><topic>Health aspects</topic><topic>Immunotherapy</topic><topic>Leukemia</topic><topic>Lymphocytes</topic><topic>Oncology</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Proteins</topic><topic>Review</topic><topic>Stem cells</topic><topic>T cell receptors</topic><topic>T cells</topic><topic>Tisagenlecleucel</topic><topic>Transplants & implants</topic><topic>Tumor necrosis factor-TNF</topic><topic>Young adults</topic><toplevel>online_resources</toplevel><creatorcontrib>Fu, Zexin</creatorcontrib><creatorcontrib>Zhou, Jinlei</creatorcontrib><creatorcontrib>Chen, Rui</creatorcontrib><creatorcontrib>Jin, Yihua</creatorcontrib><creatorcontrib>Ni, Ting</creatorcontrib><creatorcontrib>Qian, Lingbo</creatorcontrib><creatorcontrib>Xiao, Chi</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fu, Zexin</au><au>Zhou, Jinlei</au><au>Chen, Rui</au><au>Jin, Yihua</au><au>Ni, Ting</au><au>Qian, Lingbo</au><au>Xiao, Chi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cluster of differentiation 19 chimeric antigen receptor T‑cell therapy in pediatric acute lymphoblastic leukemia (Review)</atitle><jtitle>Oncology letters</jtitle><date>2020-10-01</date><risdate>2020</risdate><volume>20</volume><issue>4</issue><spage>1</spage><epage>36</epage><pages>1-36</pages><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>Chimeric antigen receptor (CAR) T cells have an unprecedented positive curative effect for hematological malignances. Most notably, cluster of differentiation 19 (CD19) CAR T-cell therapy for pediatric acute lymphoblastic leukemia is associated with a high complete remission rate and has aroused considerable attention in the medical field. However, it also causes a series of adverse reactions and increases the risk of recurrence. The present review examines the results of CD19 CAR T-cell therapy and lists its adverse effects. In addition, some of the mechanisms of recurrence are characterized and applicable strategies to address this challenging problem are proposed.</abstract><cop>Athens</cop><pub>Spandidos Publications</pub><pmid>32802160</pmid><doi>10.3892/ol.2020.11897</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-1074 |
| ispartof | Oncology letters, 2020-10, Vol.20 (4), p.1-36 |
| issn | 1792-1074 1792-1082 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7412636 |
| source | Spandidos Publications Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Acute lymphocytic leukemia Antigens B cells Cancer therapies Cell differentiation Chemotherapy Clinical medicine Clinical trials Combination drug therapy Cytokines Genetic engineering Health aspects Immunotherapy Leukemia Lymphocytes Oncology Patients Pediatrics Proteins Review Stem cells T cell receptors T cells Tisagenlecleucel Transplants & implants Tumor necrosis factor-TNF Young adults |
| title | Cluster of differentiation 19 chimeric antigen receptor T‑cell therapy in pediatric acute lymphoblastic leukemia (Review) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T22%3A52%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cluster%20of%20differentiation%2019%20chimeric%20antigen%20receptor%20T%E2%80%91cell%20therapy%20in%20pediatric%20acute%20lymphoblastic%20leukemia%20(Review)&rft.jtitle=Oncology%20letters&rft.au=Fu,%20Zexin&rft.date=2020-10-01&rft.volume=20&rft.issue=4&rft.spage=1&rft.epage=36&rft.pages=1-36&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2020.11897&rft_dat=%3Cgale_pubme%3EA635402890%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2437375546&rft_id=info:pmid/32802160&rft_galeid=A635402890&rfr_iscdi=true |